Results 31 to 40 of about 33,910 (293)

Hepatitis C virus evasion mechanisms from neutralizing antibodies [PDF]

, 2011
Hepatitis C virus (HCV) represents a major public health problem, affecting 3% of the world’s population. The majority of infected individuals develop chronic hepatitis, which can progress to cirrhosis and hepatocellular carcinoma.
Angus, Allan G.N., Arvind H. Patel, Patel, Arvind H., Caterina Di Lorenzo, Allan G. N. Angus, Lorenzo, Caterina D.   +5 more
core   +1 more source

Human immunodeficiency virus type-1 (HIV-1) continues to evolve in presence of broadly neutralizing antibodies more than ten years after infection. [PDF]

PLoS ONE, 2012
BACKGROUND: The evolution of HIV-1 and its immune escape to autologous neutralizing antibodies (Nabs) during the acute/early phases of infection have been analyzed in depth in many studies.
Antoine Chaillon, Martine Braibant, Stéphane Hué, Samia Bencharif, David Enard, Alain Moreau, Assia Samri, Henri Agut, Francis Barin   +8 more
doaj   +1 more source

Decoding broadly neutralizing antibodies: a milestone in SFTSV therapy [PDF]

EBioMedicine
Xiaoyu Zhao, Hin Chu
doaj   +2 more sources

Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate [PDF]

, 2012
The majority of broadly neutralizing antibodies to hepatitis C virus (HCV) are against conformational epitopes on the E2 glycoprotein. Many of them recognize overlapping epitopes in a cluster, designated as antigenic domain B, that contains residues G530
Wenyan Wang (171659), Bukh, J., Felix A Rey, Yong Wang (12837), Wang, Yong, Zhen-yong Keck (171653), Jannick Prentoe (162323), Lemon, S.M., Jannick Prentoe, Jens Bukh (162343), Steven K. H. Foung (171667), Lemon, Stanley M., Prentoe Jannick, Foung Steven K. H., Thomas Carlsen (171662), Carlsen, Thomas, Rey, F.A., Patel, Arvind H., Li, A.Y., Patel, A.H., Steven K H Foung, Carlsen Thomas, Bukh, Jens, Xia, J., Zhen-yong Keck, Li, Angela Ying-Jian, Wenyan Wang, Keck, Zhen-yong, Thomas Krey, Wang, Y., Rey Felix A., Yong Wang, Foung, S.K.H., Arvind H. Patel (33806), Patel, Arvind H, Lemon, Stanley M, Krey Thomas, Keck Zhen-yong, Wang Wenyan, Rey, Felix A., Prentoe, Jannick, Arvind H Patel, Bukh Jens, Stanley M Lemon, Krey, T., Angela Ying-Jian Li, Felix A. Rey (171664), Foung, Steven K H, Thomas Krey (171661), Keck, Z., Xia Jinming, Krey, Thomas, Jinming Xia (171656), Stanley M. Lemon (30543), Wang, Wenyan, Lemon Stanley M., Patel Arvind H., Rey, Felix A, Li Angela Ying-Jian, Jinming Xia, Xia, Jinming, Foung, Steven K. H., Thomas Carlsen, Wang, W., Prentoe, J., Jens Bukh, Angela Ying-Jian Li (171663), Carlsen, T., Wang Yong   +68 more
core   +1 more source

Broadly neutralizing antibodies against COVID-19

Current Opinion in Virology, 2023
The COVID-19 pandemic caused by SARS-CoV-2 has led to hundreds of millions of infections and millions of deaths, however, human monoclonal antibodies (mAbs) can be an effective treatment. Since SARS-CoV-2 emerged, a variety of strains have acquired increasing numbers of mutations to gain increased transmissibility and escape from the immune response ...
Zhou, Daming, Ren, Jingshan, Fry, Elizabeth E, Stuart, David I   +3 more
openaire   +2 more sources

Structural basis for germline antibody recognition of HIV-1 immunogens

eLife, 2016
Efforts to elicit broadly neutralizing antibodies (bNAbs) against HIV-1 require understanding germline bNAb recognition of HIV-1 envelope glycoprotein (Env).
Louise Scharf, Anthony P West Jr, Stuart A Sievers, Courtney Chen, Siduo Jiang, Han Gao, Matthew D Gray, Andrew T McGuire, Johannes F Scheid, Michel C Nussenzweig, Leonidas Stamatatos, Pamela J Bjorkman   +11 more
doaj   +1 more source

Tackling influenza with broadly neutralizing antibodies

Current Opinion in Virology, 2017
Monoclonal antibodies have revolutionized the treatment of several human diseases, including cancer, autoimmunity and inflammatory conditions and represent a new frontier for the treatment of infectious diseases. In the last decade, new methods have allowed the efficient interrogation of the human antibody repertoire from influenza immune individuals ...
Corti D, Cameroni E, Guarino B, Kallewaard NL, Zhu Q, Lanzavecchia A   +5 more
openaire   +3 more sources

In Vivo Emergence of HIV-1 Highly Sensitive to Neutralizing Antibodies [PDF]

, 2011
Background: The rapid and continual viral escape from neutralizing antibodies is well documented in HIV-1 infection. Here we report in vivo emergence of viruses with heightened sensitivity to neutralizing antibodies, sometimes paralleling the development
O'Farrell Stephen, Pellegrino, P, Williams Ian, Williams, IG, Kelly M Cheney, Áine McKnight, Anna Forsman, Cheney, Kelly M, McKnight, Áine, Cheney Kelly M., Hué, Stéphane, Forsman Anna, Marlén M I Aasa-Chapman, McKnight, A, Marlén M. I. Aasa-Chapman, Ian Williams, Aasa-Chapman, Marlén MI, Cheney, KM, O'Farrell, S, Stéphane Hué, Kelly M. Cheney, Pellegrino, Pierre, Stephen O'Farrell, Forsman, A, O'Farrell, Stephen, Pierre Pellegrino, Williams, Ian, Forsman, Anna, Aasa-Chapman Marlén M. I., Aasa-Chapman, MMI, Hué Stéphane, McKnight Áine, Pellegrino Pierre, Williams, I, Hue, S, Aasa-Chapman, MM   +35 more
core   +1 more source

Characterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco [PDF]

, 2014
The proposed clinical trial in Africa of VRC01, a potent broadly neutralizing antibody (bNAb) capable of neutralizing 91% of known HIV-1 isolates, raises concerns about testing a treatment which will be too expensive to be accessible by the most ...
Katja Klein, Julian K‐C. Ma, Klein, K, Ma, JK-C, Teh, AY, Ma, Julian K.C., Maresch, Daniel, Teh, AY-H, Klein, Katja, Ma, JK, Teh, Audrey Y.H., Audrey Y‐H. Teh, Daniel Maresch, Maresch, D   +13 more
core   +1 more source

A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies

mBio, 2020
Broadly neutralizing antibodies (bNAbs) can prevent and control an HIV-1 infection, but their breadth is invariably too limited for use as monotherapy. To address this problem, bi- and trispecific antibody-like constructs have been developed.
Meredith E. Davis-Gardner, Barnett Alfant, Jesse A. Weber, Matthew R. Gardner, Michael Farzan   +4 more
doaj   +1 more source